Print this article
- 02/07/2017

endpoint’s 500th IRT Trial Has Them Looking Ahead

Pharma Horizon

endpoint Clinical, a leading interactive response technology (IRT®) company, has launched the 500th clinical trial on its PULSE® platform, a proprietary, full-service IRT solution.

“We are excited to have met this significant milestone,” said Chuck Harris, CEO. “With our current momentum, we will hit 1000 trials at a faster pace than before, delivering on endpoint’s mission to speed new therapies to patients around the world.”

In its calendar 2016 financial year endpoint achieved another year of greater than 25 percent revenue growth, and it has expectations to accelerate that trajectory based on healthy growth within the IRT space, projected to reach upward of $1 billion by 2021.


endpoint’s strategic plan for 2017 emphasizes both technology and infrastructure investments, with a core focus on the growth of its product offerings and geographic footprint.  The first of these investments will be an expansion into Boston this spring, ensuring its clients’ needs are met with local support in yet another major biotech corridor.

endpoint will also further invest in its proprietary technologies, both the proven PULSE platform as well as the recently launched DRIVE clinical supply management hub; these tools provide end-to-end management of the clinical trial supply chain.  At endpoint’s annual User Group Meeting later this year, endpoint and its customers will discuss evolving industry needs to further ensure its products’ capabilities, ease-of-use, and scalability remain unmatched.

“I have worked alongside the endpoint team for several years now,” said Jim Esinhart, CEO at Chiltern and chairman of the endpoint board of directors. “I’ve witnessed endpoint’s commitment to strategic investment, unparalleled compared to others in the industry. Their understanding of the continuous need for technology enhancements and dedication to putting innovation into action underscores their commitment to the success of their clients.”